Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors

Bateni, Sarah B.; Coburn, Natalie; Law, Calvin; Singh, Simron; Myrehaug, Sten; Assal, Angela; Hallet, Julie

doi:10.1001/jamaoncol.2021.4531

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A population‐based analysis of the SEER registries examined the risk of developing SPMs among patients with neuroendocrine tumors between 2000 and 2016. Of 58 596 cases, 4612 (7.9%) were diagnosed with SPMs, and the 5‐year cumulative incidence was 5.4% 15 . A meta‐analysis involving 5280 patients with primary gastrointestinal carcinoids estimated that the average incidence of SPMs was 17% 16 .…”

Section: Discussionmentioning

confidence: 99%

“…Of 58 596 cases, 4612 (7.9%) were diagnosed with SPMs, and the 5-year cumulative incidence was 5.4%. 15 A meta-analysis involving 5280 patients with primary gastrointestinal carcinoids estimated that the average incidence of SPMs was 17%. 16 Also, a recent study of 2757 patients with lung and gastroenteropancreatic neuroendocrine neoplasms confirmed the increased SPMs risk, showing a 9.8% prevalence.…”

Section: Second Primary Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018

Yang

Liu

Leng

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and AimAs a result of improved survival, cancer survivors continue to remain at risk of developing second primary malignancies (SPMs). However, the association between first primary pancreatic neuroendocrine neoplasms (PanNENs) and SPMs has not been thoroughly investigated.MethodsUsing the Surveillance, Epidemiology, and End Results‐18 database, patients histologically diagnosed with PanNENs as their first malignancy between 2000 and 2018 were identified. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) and excess absolute risks per 10 000 person‐years of SPMs were calculated to estimate the risk of being diagnosed with subsequent cancers compared with the general population.ResultsA total of 489 (5.7%) PanNENs survivors developed an SPM during the follow up, with a median latency between first and second cancer diagnoses of 32.0 months. The overall SIR of SPMs was 1.30 (95% CI: 1.19, 1.42) and the excess absolute risk was 35.67 cases per 10 000 person‐years in comparison with the general population. Age 25–64 years at PanNENs diagnosis was associated with statistically higher risks for SPMs of all cancers combined. Latency stratification was significant for elevated SPMs risk between 2–23 and 84+ months after diagnosis. White patients were found to have a significantly increased incidence of SPMs (SIR: 1.23, 95% CI: 1.11, 1.35), mainly owing to the higher risk of stomach, small intestine, pancreas, kidney and renal pelvis, and thyroid cancers.ConclusionPancreatic neuroendocrine neoplasms survivors experience a significant increase in the burden of SPMs compared with the reference population. The heightened relative risk calls for careful long‐term scrutiny as part of survivorship care plans.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Second Primary Malignanciesmentioning

confidence: 99%

Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018

Yang

Liu

Leng

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Previously we have demonstrated a close association of GI tract NETs and risks for concurrent second primary malignancy[ 9 ]. A recent review of all organ NETs and second primary malignancy from SEER database demonstrated that amongst 58596 patients with NETs, 4612 patients (7.9%) presented with a secondary primary cancer, an increased absolute risk by a factor of 42.47 for all cancers per 10000 person years[ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Mixed neuroendocrine and adenocarcinoma of gastrointestinal tract: A complex diagnosis and therapeutic challenge

Shenoy

2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

In this editorial we comment on the manuscript describing a case of adenocarcinoma mixed with a neuroendocrine carcinoma of the gastroesophageal junction. Mixed neuroendocrine and non-neuroendocrine neoplasms of the gastrointestinal system are rare heterogeneous group of tumors characterized by a high malignant potential, rapid growth, and poor prognosis. Due to the rarity of these cancers, the standard therapy is poorly defined. The diagnosis of these tumors is based on combination of morphological features, immunohistochemical and neuroendocrine and epithelial cell markers. Both endocrine and epithelial cell components can act independently of each other and thus, careful grading of each component separately is required. These cancers are aggressive in nature and the potential of each component has paramount importance in the choice of treatment and response. Regardless of the organ of origin, these tumors portend poor prognosis with increased proportion of neuroendocrine component. Multidisciplinary services and strategies are required for the management of these mixed malignancies to provide the best oncological outcomes. The etiopathogenesis of these mixed tumors remains obscure but poses interesting question. We briefly discuss a few salient points in this editorial.

show abstract

Risk prediction of second primary malignancies after gynecological malignant neoplasms resection with and without radiation therapy: a population-based surveillance, epidemiology, and end results (SEER) analysis

Wang

Zhang

Xiang

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The association between post-resection radiotherapy for primary gynecological malignant neoplasms (GMNs) and the development of secondary primary malignancies (SPMs) remains a subject of debate. This study represents the first population-based analysis employing a multivariate competitive risk model to assess risk factors for this relationship and to develop a comprehensive competing-risk nomogram for quantitatively predicting SPM probabilities. Materials and methods In our study, data on patients with primary GMNs were retrospectively collected from the Epidemiology, Surveillance and End Results (SEER) database from 1973 to 2015. The incidence of secondary malignant tumors diagnosed at least six months after GMN diagnosis was compared to determine potential risk factors for SPMs in GMN patients using the Fine and Gray proportional sub-distribution hazard model. A competing-risk nomogram was constructed to quantify SPM probabilities. Results A total of 109,537 patients with GMNs were included in the study, with 76,675 and 32,862 GMN patients in the training and verification sets, respectively. The competing-risk model analysis identified age, primary tumor location, tumor grade, disease stage, chemotherapy, and radiation as risk factors for SPMs in GMN patients. Calibration curves and ROC curves in both training and verification cohorts demonstrated the predictive accuracy of the established nomogram, which exhibited a good ability to predict SPM occurrence. Conclusions This study presents the nomogram developed for quantitatively predicting SPM probabilities in GMN patients for the first time. The constructed nomogram can assist clinicians in designing personalized treatment strategies and facilitate clinical decision-making processes.

show abstract

Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors

Cited by 6 publications

References 6 publications

Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018

Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018

Mixed neuroendocrine and adenocarcinoma of gastrointestinal tract: A complex diagnosis and therapeutic challenge

Risk prediction of second primary malignancies after gynecological malignant neoplasms resection with and without radiation therapy: a population-based surveillance, epidemiology, and end results (SEER) analysis

Contact Info

Product

Resources

About